Which has better valuation and earnings, MANE or MGTX?

Veradermics has higher earnings, but lower revenue than MeiraGTx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A N/A N/A N/A MeiraGTx $81.39M 15.37 -$114.20M -$1.48 N/A

Is MANE or MGTX more profitable?

Veradermics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Veradermics' return on equity of 0.00% beat MeiraGTx's return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A MeiraGTx -151.12% -1,065.47% -54.96%

Is TNGX or MGTX more profitable?

MeiraGTx has a net margin of -151.12% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -41.54% beat MeiraGTx's return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics -151.15% -41.54% -33.44% MeiraGTx -151.12% -1,065.47% -54.96%

Does the media favor VKTX or MGTX?

In the previous week, Viking Therapeutics had 7 more articles in the media than MeiraGTx. MarketBeat recorded 9 mentions for Viking Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.54 beat Viking Therapeutics' score of 0.75 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to MGTX or EWTX?

In the previous week, Edgewise Therapeutics had 1 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for Edgewise Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.54 beat Edgewise Therapeutics' score of 1.54 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to MGTX or DNLI?

In the previous week, MeiraGTx and MeiraGTx both had 2 articles in the media. MeiraGTx's average media sentiment score of 1.54 beat Denali Therapeutics' score of 0.63 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MeiraGTx (MGTX) Competitors

$13.51 +0.97 (+7.74%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$13.72 +0.21 (+1.52%)

As of 06/30/2026 05:33 PM Eastern

Compare

MGTX vs. MANE, TNGX, VKTX, EWTX, and DNLI

Should you buy MeiraGTx stock or one of its competitors? MarketBeat compares MeiraGTx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MeiraGTx include Veradermics (MANE), Tango Therapeutics (TNGX), Viking Therapeutics (VKTX), Edgewise Therapeutics (EWTX), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry.

How does MeiraGTx compare to Veradermics?

Veradermics (NYSE:MANE) and MeiraGTx (NASDAQ:MGTX) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

In the previous week, MeiraGTx had 2 more articles in the media than Veradermics. MarketBeat recorded 2 mentions for MeiraGTx and 0 mentions for Veradermics. MeiraGTx's average media sentiment score of 1.54 beat Veradermics' score of 1.00 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradermics	Positive
MeiraGTx	Very Positive

Veradermics currently has a consensus price target of $114.20, suggesting a potential downside of 7.34%. MeiraGTx has a consensus price target of $25.83, suggesting a potential upside of 91.22%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts plainly believe MeiraGTx is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Veradermics has higher earnings, but lower revenue than MeiraGTx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	N/A	N/A
MeiraGTx	$81.39M	15.37	-$114.20M	-$1.48	N/A

67.5% of MeiraGTx shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Veradermics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Veradermics' return on equity of 0.00% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
MeiraGTx	-151.12%	-1,065.47%	-54.96%

Summary

MeiraGTx beats Veradermics on 8 of the 12 factors compared between the two stocks.

How does MeiraGTx compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and MeiraGTx (NASDAQ:MGTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

In the previous week, Tango Therapeutics and Tango Therapeutics both had 2 articles in the media. MeiraGTx's average media sentiment score of 1.54 beat Tango Therapeutics' score of 1.43 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Overall Sentiment
Tango Therapeutics	Positive
MeiraGTx	Very Positive

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tango Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Tango Therapeutics currently has a consensus price target of $41.50, suggesting a potential upside of 32.76%. MeiraGTx has a consensus price target of $25.83, suggesting a potential upside of 91.22%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts plainly believe MeiraGTx is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Tango Therapeutics has higher earnings, but lower revenue than MeiraGTx. Tango Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	72.49	-$101.59M	-$0.83	N/A
MeiraGTx	$81.39M	15.37	-$114.20M	-$1.48	N/A

MeiraGTx has a net margin of -151.12% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -41.54% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
MeiraGTx	-151.12%	-1,065.47%	-54.96%

Summary

MeiraGTx beats Tango Therapeutics on 9 of the 16 factors compared between the two stocks.

How does MeiraGTx compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and MeiraGTx (NASDAQ:MGTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 7.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Viking Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Viking Therapeutics' return on equity of -71.31% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
MeiraGTx	-151.12%	-1,065.47%	-54.96%

In the previous week, Viking Therapeutics had 7 more articles in the media than MeiraGTx. MarketBeat recorded 9 mentions for Viking Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.54 beat Viking Therapeutics' score of 0.75 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

MeiraGTx has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
MeiraGTx	$81.39M	15.37	-$114.20M	-$1.48	N/A

Viking Therapeutics presently has a consensus price target of $93.60, suggesting a potential upside of 139.94%. MeiraGTx has a consensus price target of $25.83, suggesting a potential upside of 91.22%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Viking Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Viking Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

Summary

Viking Therapeutics and MeiraGTx tied by winning 8 of the 16 factors compared between the two stocks.

How does MeiraGTx compare to Edgewise Therapeutics?

MeiraGTx (NASDAQ:MGTX) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

MeiraGTx has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	15.37	-$114.20M	-$1.48	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Edgewise Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Edgewise Therapeutics' return on equity of -32.55% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	-1,065.47%	-54.96%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

In the previous week, Edgewise Therapeutics had 1 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for Edgewise Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.54 beat Edgewise Therapeutics' score of 1.54 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

MeiraGTx presently has a consensus target price of $25.83, indicating a potential upside of 91.22%. Edgewise Therapeutics has a consensus target price of $47.30, indicating a potential upside of 16.42%. Given MeiraGTx's higher probable upside, analysts clearly believe MeiraGTx is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

MeiraGTx has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

67.5% of MeiraGTx shares are held by institutional investors. 7.4% of MeiraGTx shares are held by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

MeiraGTx beats Edgewise Therapeutics on 8 of the 15 factors compared between the two stocks.

How does MeiraGTx compare to Denali Therapeutics?

MeiraGTx (NASDAQ:MGTX) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

MeiraGTx has higher earnings, but lower revenue than Denali Therapeutics. MeiraGTx is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	15.37	-$114.20M	-$1.48	N/A
Denali Therapeutics	$330.53M	12.35	-$512.54M	-$2.88	N/A

MeiraGTx has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

MeiraGTx presently has a consensus price target of $25.83, indicating a potential upside of 91.22%. Denali Therapeutics has a consensus price target of $34.25, indicating a potential upside of 33.16%. Given MeiraGTx's higher possible upside, analysts plainly believe MeiraGTx is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Denali Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Denali Therapeutics' return on equity of -52.20% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	-1,065.47%	-54.96%
Denali Therapeutics	N/A	-52.20%	-43.86%

In the previous week, MeiraGTx and MeiraGTx both had 2 articles in the media. MeiraGTx's average media sentiment score of 1.54 beat Denali Therapeutics' score of 0.63 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Denali Therapeutics beats MeiraGTx on 9 of the 15 factors compared between the two stocks.

Get MeiraGTx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGTX vs. The Competition

Export

Metric	MeiraGTx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.16B	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-9.13	20.90	27.24	24.87
Price / Sales	15.37	341.80	544.57	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	-193.00	8.75	10.95	6.54
Net Income	-$114.20M	$23.81M	$3.57B	$336.70M
7 Day Performance	16.47%	3.60%	2.27%	2.81%
1 Month Performance	37.86%	3.72%	1.35%	0.58%
1 Year Performance	108.49%	68.80%	36.67%	31.29%

MeiraGTx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGTX MeiraGTx	2.9226 of 5 stars	$13.51 +7.7%	$25.83 +91.2%	+107.2%	$1.16B	$81.39M	N/A	300	Positive News
MANE Veradermics	N/A	$104.18 +1.4%	$114.20 +9.6%	N/A	$4.37B	N/A	N/A	19	Positive News Gap Down
TNGX Tango Therapeutics	3.2926 of 5 stars	$28.78 +1.0%	$38.42 +33.5%	+510.5%	$4.16B	$62.38M	N/A	90	Positive News Analyst Forecast
VKTX Viking Therapeutics	2.7932 of 5 stars	$35.13 +8.5%	$93.60 +166.4%	+47.2%	$4.08B	N/A	N/A	20
EWTX Edgewise Therapeutics	3.4566 of 5 stars	$37.72 +3.3%	$47.30 +25.4%	+209.9%	$4.04B	N/A	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGTX) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MeiraGTx (MGTX) Competitors

MGTX vs. MANE, TNGX, VKTX, EWTX, and DNLI

How does MeiraGTx compare to Veradermics?

Summary

How does MeiraGTx compare to Tango Therapeutics?

Summary

How does MeiraGTx compare to Viking Therapeutics?

Summary

How does MeiraGTx compare to Edgewise Therapeutics?

Summary

How does MeiraGTx compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MeiraGTx (MGTX) Competitors

MGTX vs. MANE, TNGX, VKTX, EWTX, and DNLI

How does MeiraGTx compare to Veradermics?

Does the media refer more to MANE or MGTX?

Do analysts rate MANE or MGTX?

Which has better valuation and earnings, MANE or MGTX?

Do insiders and institutionals hold more shares of MANE or MGTX?

Is MANE or MGTX more profitable?

Summary

How does MeiraGTx compare to Tango Therapeutics?

Does the media favor TNGX or MGTX?

Do insiders & institutionals have more ownership in TNGX or MGTX?

Which has more volatility and risk, TNGX or MGTX?

Do analysts prefer TNGX or MGTX?

Which has better earnings & valuation, TNGX or MGTX?

Is TNGX or MGTX more profitable?

Summary

How does MeiraGTx compare to Viking Therapeutics?

Do insiders and institutionals have more ownership in VKTX or MGTX?

Is VKTX or MGTX more profitable?

Does the media favor VKTX or MGTX?

Which has better valuation and earnings, VKTX or MGTX?

Do analysts rate VKTX or MGTX?

Which has more volatility and risk, VKTX or MGTX?

Summary

How does MeiraGTx compare to Edgewise Therapeutics?

Which has better valuation and earnings, MGTX or EWTX?

Is MGTX or EWTX more profitable?

Does the media refer more to MGTX or EWTX?

Do analysts rate MGTX or EWTX?

Which has more volatility & risk, MGTX or EWTX?

Do insiders & institutionals believe in MGTX or EWTX?

Summary

How does MeiraGTx compare to Denali Therapeutics?

Which has better earnings and valuation, MGTX or DNLI?

Which has more risk & volatility, MGTX or DNLI?

Do analysts prefer MGTX or DNLI?

Do insiders and institutionals believe in MGTX or DNLI?

Is MGTX or DNLI more profitable?

Does the media refer more to MGTX or DNLI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools